Reserved area

Credentials and contents in the EryDel “RESERVED AREA” are strictly confidential and the access is authorized only for the medical staff operating the EDS in the ATTeST study. The Content of the “RESERVED AREA” should not be copied, distributed or reproduced in whole or in part, nor distributed to any third party if not for the  training purpose of authorized EDS Operators. The Content of the “RESERVED AREA” is only for medically trained staff.

I Agree

Advisory Board 

Prof. Carlo Brugnara

Carlo Brugnara, MD is Professor of Pathology at Harvard Medical School and Director of the Hematology Laboratory at Children's Hospital Boston.

He received his MD from the University of Verona, Italy in 1979.In 1982 he joined as a postdoctoral fellow the laboratory of Dr. Daniel Tosteson in the Department of Physiology at Harvard Medical School. He trained in Clinical Pathology and Transfusion Medicine at Brigham and Women's Hospital in Boston from 1986 to 1990, and holds board certifications in both specialties. In 1992, he joined the Department of Laboratory Medicine at Children's Hospital as Director of the Hematology laboratory. Dr. Brugnara's basic research interests are focused on transport of ions across cell membrane. His studies have identified the role of specific transport proteins in inducing erythrocyte dehydration in sickle cell disease and identified new therapeutic approaches for sickle cell anemia. His most recent research has focused on genetic determinant of erythrocyte hydration and on the interaction between erythrocyte ion transporters of the erythrocyte and the changes induced by the intracellular growth of Plasmodium Falciparum, one of the causative agents of malaria infection.

Dr. Brugnara's clinical laboratory-based research has been focused on the use of hematological parameters to assess the balance between iron availability and erythropoiesis. He has described the appearance of functional iron deficiency in normal subjects treated with recombinant human erythropoietin (r-HuEPO) based on the particular flow cytometric characteristics of erythrocytes and reticulocytes. He has shown the clinical value of reticulocyte parameters in the setting of r-HuEPO use and in the diagnosis of iron deficiency in children.

Dr. Brugnara is a fellow of the American Society of Clinical Investigation, the Association of American Physicians, and the Academy of Clinical Laboratory Physicians and Scientists. He is the Editor-in-Chief of the American Journal of Hematology.

Dr. Brugnara is a named inventor in 17 US patents, and is the author/coauthor of more than 210 original articles, book chapters and invited reviews, as well as 8 books.

Prof. Vladimir Muzykantov

Vladimir R. Muzykantov, M.D., Ph.D., is professor of Pharmacology and Medicine, Director Center for Translational Targeted Therapeutics and Nanomedicine, Institute for Translational medicine and Therapeutics, University of Pennsylvania School of Medicine, PENN. Dr. Muzykantov obtained his M.D. degree (Internal Medicine) from Moscow Medical School in 1980 and Ph.D. (Biochemistry) from Russian National Cardiology Research Center in 1985. Prior to joining the University of Pennsylvania (PENN) in 1993, he was a Senior Investigator in Russian National Cardiology Research Center in Moscow, where he conducted research in vascular drug targeting. He has published ~180 peer reviewed papers on drug delivery and vascular biology in the leading journals including numerous papers in Nature Biotechnology, PNAS USA, Blood, FASEB J., AJP and JPET. He authored ~30 chapters and reviews. In 2003, Dr. Muzykantov edited a book "Biomedical Aspects of Drug Targeting" published by Kluwer Academic Press. He has been a recipient of the Established Investigator Award (1996-2000) and Bugher Stroke Award (2000-2004) from the American Heart Association. He gave numerous talks, including Gordon Research Conferences on Carriers for Drug Delivery (2002, 2008), Oxidative Stress (2004), and Endothelium (2004).

He was a Keynote Speaker at several forums in the USA and Europe. He chaired Transatlantic Conference on Imaging Target Molecular Signatures in the Lungs (Luzerne, 2009) and the Gordon Research Conference on Carriers for Drug Delivery (2012).

Dr Muzykantov directs a research lab at PENN continuously funded by the NIH, DOD, AHA and other sources since 1996. His research is focused on vascular targeting of biotherapeutics and imaging probes. He designs and explores targeting strategies employing affinity carriers directed to vascular targets for site-specific delivery and guided effects of anti-inflammatory, anti-thrombotic and antioxidant therapeutics. His team employs bioconjugation and bioengineering, recombinant fusion and mutant proteins, polymer nanocarriers for drug delivery, cell and molecular biology approaches and imaging techniques. Studies on pharmacokinetics, targeting, subcellular addressing, cellular traffic, activity and effects of targeted drugs are performed in models including cell cultures, perfused organs and in animal models of inflammation, ischemia, oxidative and thrombotic stress. He devised a paradigm-shifting strategy and biotech platform for new class of recombinant mutant protein pro-drugs using blood cells for targeted drug delivery. Ongoing animal studies show that this new class of targeted biotherapeutics offers an unprecedented degree of spatiotemporal control of interventions. This approach converts problematic therapies with limited efficacy and therapeutic time window, marred by grave side effects, into a safe and effective rapid short-term thromboprophylaxis. This allows prevent thrombotic occlusions in venous, arterial, pulmonary, cerebral and peripheral microcirculatory vessels in mice, rats and pigs, without detectable harmful side effects and bleeding, even if animals underwent major surgery or traumatic brain injury, just minutes prior treatment.

Dr. Muzykantov is dedicated to industrial and clinical translation of his basic research. He holds a portfolio of intellectual property including about 15 issued US Patents, patents issued in Australia and European Union, several pending US Patents and recently filed disclosures on drug delivery.

Where We Are